New Jersey, USA-based speciality pharma company Fonseca Biosciences has announced the launch of Xtoro (finafloxacin otic suspension), 0.3% for the treatment of acute otitis externa (AOE), commonly ...
Xtoro (finafloxacin otic suspension) 0.3% is now commercially available to treat acute otitis externa in patients aged 1 year and older. Finafloxacin, the active ingredient of Xtoro, is a ...
Launch follows FDA approval of the Prior Approval Supplement required for commercial manufacturing, clearing the final regulatory hurdle to U.S. commercialization of the first new molecular entity ...
Fonseca Biosciences, a specialty pharmaceutical company commercializing clinically differentiated pharmaceutical products, today announced the launch of XTORO ® (finafloxacin otic suspension), 0.3% ...
Sherri Gordon, CLC is a certified professional life coach, author, and journalist covering health and wellness, social issues, parenting, and mental health. She also has a certificate of completion ...
The hospital-at-home (H@H) model — where patients receive acute level care in their homes, rather than in a hospital — has emerged as an innovative and promising approach to provide high quality care ...
aWesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Perth, WA, Australia bDepartment of Infectious Diseases, Perth Children's Hospital, Perth, WA, Australia ...
cDivision of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA Acute liver failure (ALF) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results